



Vie Ventures, New Life Sciences Venture Capital Firm, Launches to Advance Next Generation Therapies for Autoimmune Diseases

- *Co-founded by veteran life sciences investors Steven St. Peter, M.D., and Luke Evnin, Ph.D.*
- *Strategy focused on bridging traditional biotech venture investing with patient-centric, disease-focused philanthropy*
- *Supported by strong and expanding network of strategic collaborators from across the biotech and disease philanthropy ecosystems*

BOSTON — July 9, 2025 — [Vie Ventures](#), a new life sciences investment firm focused on bridging venture capital and disease philanthropy to develop breakthrough therapies for patients, today announced its official launch. Vie Ventures will invest alongside other leading venture capital investors and strategic partners primarily in Series B and C-stage private biotech companies focused on advancing novel therapeutics for autoimmune disease and other disorders of the immune system, an area of significant unmet medical need. Vie Ventures is co-founded by Steven St. Peter, M.D., and Luke Evnin, Ph.D., who each bring to the firm a strong track record of life sciences investing and operational leadership.

Drs. St. Peter and Evnin previously worked together for a decade at MPM Capital, where they invested three successive venture capital funds. Additionally, they bring to Vie Ventures deep personal connections to autoimmune disease and philanthropy. Most recently, Dr. St. Peter served as Managing Director of The T1D Fund, the venture philanthropy arm of Breakthrough T1D (formerly known as JDRF) that is focused on equity investments in companies pursuing therapies for type 1 diabetes (T1D). Under his leadership, the T1D Fund grew to become one of the largest disease-focused venture philanthropy funds in the world, with more than \$200 million in assets. Dr. Evnin, who co-founded MPM Capital, serves as Chairman of the Scleroderma Research Foundation (SRF), where he has served on the Board of Directors for over 25 years. Under his leadership, the SRF has pursued bold new research models, exemplified by the recently launched CONQUEST clinical trial platform for scleroderma.

Vie Ventures believes participation in life sciences venture capital from across the biotech ecosystem – disease-focused philanthropies, research foundations, and biopharmaceutical companies – is critical to translating discovery research into development towards regulatory approval to achieve our mission of advancing innovative therapeutics for patients. The firm has launched with enthusiastic support from a strong and growing coalition of strategic collaborators that have funded billions of dollars of discovery research. The firm's initial strategic collaborators include Crohn's and Colitis Foundation, Lupus Research Alliance, National Multiple Sclerosis Society, Scleroderma Research Foundation, and Sjögren's Foundation. Vie Ventures is also guided by Lou DeGennaro, Ph.D., the former CEO of the Leukemia &

Lymphoma Society, who serves as a Senior Advisor and leads the firm's strategic collaborator engagement.

"As novel technologies continues to enable breakthrough treatments and potential for prevention, there has never been a more exciting time in immunology. However, despite the rapid innovation taking place within biotechnology, significant unmet patient needs remain," said Dr. St. Peter, Managing Director of Vie Ventures. "We see a compelling opportunity to leverage our team's decades of differentiated experience to serve as a bridge between disease-focused philanthropies and the for-profit world funding therapeutics. This bridge is unique, and we believe it will enable us to make more informed investment decisions, be a value-added investment partner for our portfolio companies, and increase the probability they succeed. We look forward to being the partner of choice for both investors and therapeutic companies creating next generation therapies and cures."

"I'm excited to reunite with Steven and leverage our shared passion for discovering and advancing groundbreaking drug discovery companies focused on cross-autoimmune disease initiatives that have the potential to bring innovative therapeutics to market and change the standard of care," said Dr. Evnin, Senior Advisor at Vie Ventures. "As someone that has long been a champion of venture philanthropy and patient-centered innovation, biopharmaceutical companies need investors who can provide more than just capital: they can benefit from partners with expertise within distinct disease-focused ecosystems. That's why we founded Vie Ventures and why we believe we're uniquely positioned to bring these ecosystems together to achieve our mission of bringing life-changing therapies to patients in need."

The co-founders of Vie Ventures have aligned financial incentives with impact by pledging a share of their own proceeds and time to philanthropic efforts including the formation of Vie Ventures Foundation. Vie Ventures Foundation is a public charity whose mission is to accelerate innovation in the prevention, diagnosis, and treatment of autoimmune and inflammatory diseases.

###

About Vie Ventures

Vie Ventures is a life sciences investment firm operating at the intersection of venture capital and disease philanthropy. Vie Ventures invests alongside other leading venture capital investors and strategic partners in private biotech companies focused on advancing novel therapeutics for autoimmune disease and other disorders of the immune system, an area of significant unmet medical need. Our team leverages decades of experience, a proven track record in life sciences venture capital, a returns-oriented approach, and a network of strategic collaborators from across the biotech and disease philanthropy ecosystems to advance life-changing therapies and cures for patients. To learn more, visit vieventures.com

Media Contact:

Scott Lessne
Stanton
(646) 502-3569
slessne@stantonprm.com